References
- Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC (eds). The nonfermentative gram-negative bacil-li. In: Diagnostic Microbiology, Fifth edition. Lippincott-Raven Publishers, Philadelphia 1997; 253-309.
- Cheng NC, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, et al. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist. 2005 win-ter; 11: 330-341.
- Zhanel CC, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64: 63–88
- Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI document M100-S15, vol. 25. Clinical and Laboratory Standards Institute, Wayne Pa.
- Esen S, Leblebicioglu H. Prevalence of nosocomial infec-tions at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis. 2004; 36: 144–148
- Akcam FZ, Karaaslan D, Dogan M, Yayli G. Microbiological surveillance in the intensive care unit: a tertiary hospital experience. Med Sci Monit. 2006; 12: CR81-85.
- Shaw KJ, Hare RS, Sabatelli FJ, Rizzo M, Cramer CA, Naples L, et al. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob Agents Chemother 1991; 35: 2253–2261
- Centers for Disease Control and Prevention. Nosocomial infection surveillance summary. MMWR. 1987; 35: 17–29
- Craven DE, Steger KA, Barber TW. Preventing nosoco-mial pneumonia: State of the art and perspectives for the 1990's. Am J Med. 1991; 91 (3B): 44-53
- Bergogne-Berezin E, Towner KJ. Acinetobacter spp. As nosocomial pathogens: Microbiological, clinical, and epi-demiological features. Clin Microbiol Rev 1996; 9: 148–165.
- Greer ND. Tigecycline (Tygacil): the first in the glycylcy-dine class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19: 155-161.
- Livermore DM. Tigecycline: what is it, and where should it be used? JAC 1995; 56: 611–614.
- Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ, Spanish Group of Tigecycline. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother 2002; 46: 892–895.